# Edifice Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/edifice-health

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.edificehealth.com
- Total disclosed funding: $15M
- Latest round: Series A (Apr 9, 2021)
- Investors on record: 9

## About

Edifice Health, Inc. is a US-based company specializing in chronic inflammation monitoring solutions through its innovative Inflammatory Age® test, leveraging cutting-edge technology for healthcare advancements.Founded in 2018 in San Mateo, US, Edifice Health, Inc. focuses on chronic inflammation management. The company's Inflammatory Age® test stems from a decade-long NIH-funded study at Stanford University. David Furman, the founder, has experience in health-focused ventures. In April 2021, the company raised USD 13.85 mn in Series A funding led by Leaps by Bayer, alongside other investors, bringing total funding to USD 13.85 mn with a current valuation of USD 22.41 mn.Edifice Health delivers innovative solutions for monitoring and managing chronic inflammation, highlighted by its core product, the Inflammatory Age® test. This test utilizes advanced ‘omics’ technology and artificial intelligence, producing a composite biomarker score that provides insights into an individual's inflammatory and immune health. Healthcare providers are the primary users, employing these testing services for early disease detection and preventive health strategies.Edifice Health generates revenue by partnering with healthcare providers to offer the Inflammatory Age® testing service. This business model includes contractual agreements with clinics and physicians, facilitating comprehensive health assessments. Typical revenue streams consist of subscription models for ongoing testing services and direct service fees for individual tests, ensuring integration of these offerings into patient care protocols.In April 2021, Edifice Health raised USD 13.85 mn in Series A funding to solidify its foundation in immunological science and expand its workforce. The company plans to design and launch new products aimed at enhancing chronic disease management, with targeted expansion into new geographical markets expected by 2023. The recent funding will support these growth initiatives and facilitate further advancements in their product offerings.

## Funding rounds

- Series A, Apr 9, 2021, $14M — Paladin Capital Group, Alafi Capital, Shanda Capital, Vertical Venture Partners, Ataraxia Capital Partners, Ahren Innovation Capital, Leaps by Bayer, Taisho Pharmaceutical Co., Ltd.
- Seed, Jan 1, 2019, $1.5M — Better Food Ventures

## Investors

- Better Food Ventures (https://capitalatlas.ai/funds/better-food-ventures) — Seed
- Paladin Capital Group (https://capitalatlas.ai/funds/paladin-capital-group) — Series A
- Alafi Capital (https://capitalatlas.ai/funds/alafi-capital) — Series A
- Shanda Capital — Series A
- Vertical Venture Partners (https://capitalatlas.ai/funds/vertical-venture-partners) — Series A
- Ataraxia Capital Partners (https://capitalatlas.ai/funds/ataraxia-capital-partners) — Series A
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- Taisho Pharmaceutical Co., Ltd. — Series A